Calendar

pharmadog

Week of Apr 27, 2026

Apr 30, 2026filing105d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026filing105d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

full page →ranibizumab biosimilar →source: globaldata

Apr 30, 2026phase 0 trial completion105d agoRuijin Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

Therapy area: Central Nervous System, Dermatology. Indication: Burns, Pain, Sedation

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 0 trial completion105d agoShanghai Jiao Tong University — insulin (Phase 0 Trial Completion)insulin

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →insulin →source: globaldata

Apr 30, 2026phase 0 trial completion105d agoFoundation for the Promotion of Health and Biomedical Research of Valencia — Aquacel Ag + (Phase 0 Trial Completion)Aquacel Ag +

Therapy area: Dermatology. Indication: Pressure Ulcers

full page →Aquacel Ag + →source: globaldata

Apr 30, 2026phase 1 completion105d agoShenzhen Digestive System Disease Clinical Medicine Research Center — tegoprazan (Phase I Trial Completion)tegoprazan

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →tegoprazan →source: globaldata

Apr 30, 2026phase 1 completion105d agoIlife Consulting Sarl — PST-611 (Phase I Trial Completion)PST-611

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

full page →PST-611 →source: globaldata

Apr 30, 2026phase 1 completion105d agoMAXVAX Biotechnology Co Ltd — MKK-900 (Phase I Trial Completion)MKK-900

Therapy area: Infectious Disease. Indication: Respiratory Syncytial Virus (RSV) Infections

full page →MKK-900 →source: globaldata

Apr 30, 2026phase 1 completion105d agoJohns Hopkins University — ciprofloxacin (Phase I Trial Completion)ciprofloxacin

Therapy area: Infectious Disease. Indication: Bacillary Dysentery (Shigellosis)

full page →ciprofloxacin →source: globaldata

Apr 30, 2026phase 1 initiation105d agoGilead Sciences Inc — GS-1701 (Phase I Trial Initiation)GS-1701

Therapy area: Infectious Disease. Indication: Unspecified Infectious Diseases

full page →GS-1701 →source: globaldata

Apr 30, 2026phase 1 initiation105d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

full page →VC-005 →source: globaldata

Apr 30, 2026phase 1 initiation105d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

full page →MK-6050 →source: globaldata

Apr 30, 2026phase 1 initiation105d agoThe National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)DASATINIB

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →DASATINIB →source: globaldata

Apr 30, 2026phase 1 2 completion105d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion105d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

Therapy area: Dermatology. Indication: Vitiligo

full page →afamelanotide →source: globaldata

Apr 30, 2026phase 1 2 completion105d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 2 completion105d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Dermatology. Indication: Burns

full page →ayurvedic medicine →source: globaldata

Apr 30, 2026phase 2 completion105d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion105d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata

Apr 30, 2026phase 2 completion105d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion105d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

Apr 30, 2026phase 2 completion105d agoJetema Co Ltd — JTM-102 (Phase II Trial Completion)JTM-102

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →JTM-102 →source: globaldata

Apr 30, 2026phase 2 completion105d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion105d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

full page →recombinant type III humanized collagen →source: globaldata

Apr 30, 2026phase 2 completion105d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata

← prev

page 2 of 2

Week of Apr 27, 2026